Skip to main navigation Skip to search Skip to main content

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PDL1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Project: Research

Project Details

StatusActive
Effective start/end date08/5/25 → 09/1/28

Funding

  • Henlius USA Incorporated: $27,924.00